211 related articles for article (PubMed ID: 9459155)
1. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
Bontenbal M; Foekens JA; Lamberts SW; de Jong FH; van Putten WL; Braun HJ; Burghouts JT; van der Linden GH; Klijn JG
Br J Cancer; 1998; 77(1):115-22. PubMed ID: 9459155
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.
Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN
Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
[TBL] [Abstract][Full Text] [Related]
4. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels.
Canobbio L; Cannata D; Miglietta L; Boccardo F
Anticancer Res; 1995; 15(6B):2687-90. PubMed ID: 8669848
[TBL] [Abstract][Full Text] [Related]
5. Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergoline.
Lissoni P; Vaghi M; Villa S; Bodraska A; Cerizza L; Tancini G; Gardani GS
Anticancer Res; 2003; 23(1B):733-6. PubMed ID: 12680176
[TBL] [Abstract][Full Text] [Related]
6. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
[TBL] [Abstract][Full Text] [Related]
7. Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy.
Helle SI; Mietlowski W; Guastalla JP; Szakolczai I; Bajetta E; Sommer H; Baltali E; Pinter T; Csepreghy M; Ottestad L; Boni C; Bryce C; Klijn JG; Lønning PE
Eur J Cancer; 2005 Mar; 41(5):694-701. PubMed ID: 15763644
[TBL] [Abstract][Full Text] [Related]
8. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
9. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
10. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
11. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
12. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
[TBL] [Abstract][Full Text] [Related]
13. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
Pyrhönen S; Valavaara R; Modig H; Pawlicki M; Pienkowski T; Gundersen S; Bauer J; Westman G; Lundgren S; Blanco G; Mella O; Nilsson I; Hietanen T; Hindy I; Vuorinen J; Hajba A
Br J Cancer; 1997; 76(2):270-7. PubMed ID: 9231932
[TBL] [Abstract][Full Text] [Related]
14. [A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer].
Sommer H; Pröhl-Steimer B; Bajetta E; Haus U; Janni W; Kay A
Zentralbl Gynakol; 2001 Oct; 123(10):557-61. PubMed ID: 11753809
[TBL] [Abstract][Full Text] [Related]
15. Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
Uchino J; Samejima N; Tanabe T; Hayasaka H; Mito M; Hata Y; Asaishi K
Br J Cancer; 1994 Apr; 69(4):767-71. PubMed ID: 8142265
[TBL] [Abstract][Full Text] [Related]
16. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
17. The place of chemotherapy in the treatment of early breast cancer.
Buzdar A
Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):16-20. PubMed ID: 9741784
[TBL] [Abstract][Full Text] [Related]
18. A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer.
Fentiman IS; Howell A; Hamed H; Lee SM; Ranson M; Wall J; Chaudary MA; Ash CM; Gregory WM; Sellwood RA
Br J Cancer; 1994 Oct; 70(4):729-31. PubMed ID: 7917929
[TBL] [Abstract][Full Text] [Related]
19. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen and fenretinide in women with metastatic breast cancer.
Zujewski J; Pai L; Wakefield L; Giusti R; Dorr FA; Flanders C; Caruso R; Kaiser M; Goodman L; Merino M; Gossard M; Noone MA; Denicoff A; Venzon D; Cowan KH; O'Shaughnessy JA
Breast Cancer Res Treat; 1999 Oct; 57(3):277-83. PubMed ID: 10617304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]